Cyclosporine or Tacrolimus: Which Is the Better Partner for Myfortic or CellCept?
Abstract Background Mycophenolic acid (MPA) pharmacokinetics using the mycophenolate mofetil (CellCept) formulation are known to differ between patients receiving tacrolimus (FK) or cyclosporine (CyA), but only limited data exist concerning concomitant use of FK or CyA with enteric-coated mycophenol...
Gespeichert in:
| Veröffentlicht in: | Transplantation proceedings 2012, Vol.44 (1), p.137-139 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 139 |
|---|---|
| container_issue | 1 |
| container_start_page | 137 |
| container_title | Transplantation proceedings |
| container_volume | 44 |
| creator | Lee, P.-C Chang, S.-S Shieh, S.-C Wu, Z.-C Wang, W.-M Wang, J.-D Hung, C.-J Lin, Y.-J Chou, T.-C Chan, R.-H |
| description | Abstract Background Mycophenolic acid (MPA) pharmacokinetics using the mycophenolate mofetil (CellCept) formulation are known to differ between patients receiving tacrolimus (FK) or cyclosporine (CyA), but only limited data exist concerning concomitant use of FK or CyA with enteric-coated mycophenolate sodium (EC-MPS; Myfortic). This retrospective study compared the drug interactions with the mycophenolic acid blood levels using different immunosuppressants and their relation to graft survival. Patients and methods We studied MPA levels in posttransplant sera from 298 renal transplant recipients. Results Patients receiving immunosuppression with CyA + Myfortic showed 94% at 5- and 10-year graft survivals, which were better than CyA + CellCept (75%, 63%). This combination suppressed posttransplant human leukocyte antigen (HLA) antibody development significantly ( P = .03) with higher MPA levels. Conclusion Patients immunosuppressed with CyA + Myfortic showed higher MPA levels and lower posttransplant HLA antibody development as well as the best graft survival. CyA + Myfortic or FK + Cellcept may be better combinations. |
| doi_str_mv | 10.1016/j.transproceed.2011.12.023 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_920370313</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S004113451101685X</els_id><sourcerecordid>920370313</sourcerecordid><originalsourceid>FETCH-LOGICAL-c464t-6248f6a71c0e7b8c2e285f8d4294e810172fd50b9dd56ad6cb2a6fb6fbb50423</originalsourceid><addsrcrecordid>eNqNkttq3DAQhkVpaLZpXqGYQumVHZ1sy7lIad2cIKUtWWjvhCyPWW289laSA_v2HbMbWnJVEBqE_vln5mMIecdoxigrztZZ9GYIWz9agDbjlLGM8Yxy8YIsmCpFygsuXpIFpZKlTMj8mLwOYU3xzaV4RY45F4zmlVqQH_XO9mPYjt4NkIw-WRrrx95tpnCe_Fw5u0puQxJXkHyGGMEn342PA8YOtV93eEdn57wa-r6Gbfz4hhx1pg9weognZHl1uaxv0rtv17f1p7vUykLGtOBSdYUpmaVQNspy4CrvVCt5JUHhnCXv2pw2VdvmhWkL23BTdA2eJscxxAn5sLdFDL8nCFFvXLDYhBlgnIKuOBUlFUyg8nyvxMFC8NDprXcb43eaUT0D1Wv9L1A9A9WMawSKyW8PZaZmg39PqU8EUfD-IDDBmr5DI-vCX11esUopibovex0gk0cHXgfrYLDQOg826nZ0_9fPxTMb27vBYeUH2EFYj5MfkLpmOmCCvp9XYN4ANhur_Jf4A4WHr4s</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>920370313</pqid></control><display><type>article</type><title>Cyclosporine or Tacrolimus: Which Is the Better Partner for Myfortic or CellCept?</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Lee, P.-C ; Chang, S.-S ; Shieh, S.-C ; Wu, Z.-C ; Wang, W.-M ; Wang, J.-D ; Hung, C.-J ; Lin, Y.-J ; Chou, T.-C ; Chan, R.-H</creator><creatorcontrib>Lee, P.-C ; Chang, S.-S ; Shieh, S.-C ; Wu, Z.-C ; Wang, W.-M ; Wang, J.-D ; Hung, C.-J ; Lin, Y.-J ; Chou, T.-C ; Chan, R.-H</creatorcontrib><description>Abstract Background Mycophenolic acid (MPA) pharmacokinetics using the mycophenolate mofetil (CellCept) formulation are known to differ between patients receiving tacrolimus (FK) or cyclosporine (CyA), but only limited data exist concerning concomitant use of FK or CyA with enteric-coated mycophenolate sodium (EC-MPS; Myfortic). This retrospective study compared the drug interactions with the mycophenolic acid blood levels using different immunosuppressants and their relation to graft survival. Patients and methods We studied MPA levels in posttransplant sera from 298 renal transplant recipients. Results Patients receiving immunosuppression with CyA + Myfortic showed 94% at 5- and 10-year graft survivals, which were better than CyA + CellCept (75%, 63%). This combination suppressed posttransplant human leukocyte antigen (HLA) antibody development significantly ( P = .03) with higher MPA levels. Conclusion Patients immunosuppressed with CyA + Myfortic showed higher MPA levels and lower posttransplant HLA antibody development as well as the best graft survival. CyA + Myfortic or FK + Cellcept may be better combinations.</description><identifier>ISSN: 0041-1345</identifier><identifier>EISSN: 1873-2623</identifier><identifier>DOI: 10.1016/j.transproceed.2011.12.023</identifier><identifier>PMID: 22310598</identifier><identifier>CODEN: TRPPA8</identifier><language>eng</language><publisher>Amsterdam: Elsevier Inc</publisher><subject>Antibacterial agents ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Biological and medical sciences ; Cyclosporine - therapeutic use ; Drug Interactions ; Drug Monitoring ; Drug Therapy, Combination ; Fundamental and applied biological sciences. Psychology ; Fundamental immunology ; Graft Rejection - immunology ; Graft Rejection - prevention & control ; Graft Survival - drug effects ; Histocompatibility - drug effects ; HLA Antigens - immunology ; Humans ; Immunosuppressive Agents - therapeutic use ; Isoantibodies - blood ; Kidney Transplantation - immunology ; Medical sciences ; Mycophenolic Acid - analogs & derivatives ; Mycophenolic Acid - blood ; Mycophenolic Acid - pharmacokinetics ; Mycophenolic Acid - therapeutic use ; Pharmacology. Drug treatments ; Retrospective Studies ; Surgery ; Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases ; Tacrolimus - therapeutic use ; Taiwan ; Tissue, organ and graft immunology ; Treatment Outcome</subject><ispartof>Transplantation proceedings, 2012, Vol.44 (1), p.137-139</ispartof><rights>Elsevier Inc.</rights><rights>2012 Elsevier Inc.</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2012 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c464t-6248f6a71c0e7b8c2e285f8d4294e810172fd50b9dd56ad6cb2a6fb6fbb50423</citedby><cites>FETCH-LOGICAL-c464t-6248f6a71c0e7b8c2e285f8d4294e810172fd50b9dd56ad6cb2a6fb6fbb50423</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.transproceed.2011.12.023$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>310,311,315,781,785,790,791,3551,4025,4051,4052,23934,23935,25144,27927,27928,27929,45999</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25919884$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22310598$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lee, P.-C</creatorcontrib><creatorcontrib>Chang, S.-S</creatorcontrib><creatorcontrib>Shieh, S.-C</creatorcontrib><creatorcontrib>Wu, Z.-C</creatorcontrib><creatorcontrib>Wang, W.-M</creatorcontrib><creatorcontrib>Wang, J.-D</creatorcontrib><creatorcontrib>Hung, C.-J</creatorcontrib><creatorcontrib>Lin, Y.-J</creatorcontrib><creatorcontrib>Chou, T.-C</creatorcontrib><creatorcontrib>Chan, R.-H</creatorcontrib><title>Cyclosporine or Tacrolimus: Which Is the Better Partner for Myfortic or CellCept?</title><title>Transplantation proceedings</title><addtitle>Transplant Proc</addtitle><description>Abstract Background Mycophenolic acid (MPA) pharmacokinetics using the mycophenolate mofetil (CellCept) formulation are known to differ between patients receiving tacrolimus (FK) or cyclosporine (CyA), but only limited data exist concerning concomitant use of FK or CyA with enteric-coated mycophenolate sodium (EC-MPS; Myfortic). This retrospective study compared the drug interactions with the mycophenolic acid blood levels using different immunosuppressants and their relation to graft survival. Patients and methods We studied MPA levels in posttransplant sera from 298 renal transplant recipients. Results Patients receiving immunosuppression with CyA + Myfortic showed 94% at 5- and 10-year graft survivals, which were better than CyA + CellCept (75%, 63%). This combination suppressed posttransplant human leukocyte antigen (HLA) antibody development significantly ( P = .03) with higher MPA levels. Conclusion Patients immunosuppressed with CyA + Myfortic showed higher MPA levels and lower posttransplant HLA antibody development as well as the best graft survival. CyA + Myfortic or FK + Cellcept may be better combinations.</description><subject>Antibacterial agents</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Biological and medical sciences</subject><subject>Cyclosporine - therapeutic use</subject><subject>Drug Interactions</subject><subject>Drug Monitoring</subject><subject>Drug Therapy, Combination</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Fundamental immunology</subject><subject>Graft Rejection - immunology</subject><subject>Graft Rejection - prevention & control</subject><subject>Graft Survival - drug effects</subject><subject>Histocompatibility - drug effects</subject><subject>HLA Antigens - immunology</subject><subject>Humans</subject><subject>Immunosuppressive Agents - therapeutic use</subject><subject>Isoantibodies - blood</subject><subject>Kidney Transplantation - immunology</subject><subject>Medical sciences</subject><subject>Mycophenolic Acid - analogs & derivatives</subject><subject>Mycophenolic Acid - blood</subject><subject>Mycophenolic Acid - pharmacokinetics</subject><subject>Mycophenolic Acid - therapeutic use</subject><subject>Pharmacology. Drug treatments</subject><subject>Retrospective Studies</subject><subject>Surgery</subject><subject>Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases</subject><subject>Tacrolimus - therapeutic use</subject><subject>Taiwan</subject><subject>Tissue, organ and graft immunology</subject><subject>Treatment Outcome</subject><issn>0041-1345</issn><issn>1873-2623</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkttq3DAQhkVpaLZpXqGYQumVHZ1sy7lIad2cIKUtWWjvhCyPWW289laSA_v2HbMbWnJVEBqE_vln5mMIecdoxigrztZZ9GYIWz9agDbjlLGM8Yxy8YIsmCpFygsuXpIFpZKlTMj8mLwOYU3xzaV4RY45F4zmlVqQH_XO9mPYjt4NkIw-WRrrx95tpnCe_Fw5u0puQxJXkHyGGMEn342PA8YOtV93eEdn57wa-r6Gbfz4hhx1pg9weognZHl1uaxv0rtv17f1p7vUykLGtOBSdYUpmaVQNspy4CrvVCt5JUHhnCXv2pw2VdvmhWkL23BTdA2eJscxxAn5sLdFDL8nCFFvXLDYhBlgnIKuOBUlFUyg8nyvxMFC8NDprXcb43eaUT0D1Wv9L1A9A9WMawSKyW8PZaZmg39PqU8EUfD-IDDBmr5DI-vCX11esUopibovex0gk0cHXgfrYLDQOg826nZ0_9fPxTMb27vBYeUH2EFYj5MfkLpmOmCCvp9XYN4ANhur_Jf4A4WHr4s</recordid><startdate>2012</startdate><enddate>2012</enddate><creator>Lee, P.-C</creator><creator>Chang, S.-S</creator><creator>Shieh, S.-C</creator><creator>Wu, Z.-C</creator><creator>Wang, W.-M</creator><creator>Wang, J.-D</creator><creator>Hung, C.-J</creator><creator>Lin, Y.-J</creator><creator>Chou, T.-C</creator><creator>Chan, R.-H</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>2012</creationdate><title>Cyclosporine or Tacrolimus: Which Is the Better Partner for Myfortic or CellCept?</title><author>Lee, P.-C ; Chang, S.-S ; Shieh, S.-C ; Wu, Z.-C ; Wang, W.-M ; Wang, J.-D ; Hung, C.-J ; Lin, Y.-J ; Chou, T.-C ; Chan, R.-H</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c464t-6248f6a71c0e7b8c2e285f8d4294e810172fd50b9dd56ad6cb2a6fb6fbb50423</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Antibacterial agents</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Biological and medical sciences</topic><topic>Cyclosporine - therapeutic use</topic><topic>Drug Interactions</topic><topic>Drug Monitoring</topic><topic>Drug Therapy, Combination</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Fundamental immunology</topic><topic>Graft Rejection - immunology</topic><topic>Graft Rejection - prevention & control</topic><topic>Graft Survival - drug effects</topic><topic>Histocompatibility - drug effects</topic><topic>HLA Antigens - immunology</topic><topic>Humans</topic><topic>Immunosuppressive Agents - therapeutic use</topic><topic>Isoantibodies - blood</topic><topic>Kidney Transplantation - immunology</topic><topic>Medical sciences</topic><topic>Mycophenolic Acid - analogs & derivatives</topic><topic>Mycophenolic Acid - blood</topic><topic>Mycophenolic Acid - pharmacokinetics</topic><topic>Mycophenolic Acid - therapeutic use</topic><topic>Pharmacology. Drug treatments</topic><topic>Retrospective Studies</topic><topic>Surgery</topic><topic>Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases</topic><topic>Tacrolimus - therapeutic use</topic><topic>Taiwan</topic><topic>Tissue, organ and graft immunology</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lee, P.-C</creatorcontrib><creatorcontrib>Chang, S.-S</creatorcontrib><creatorcontrib>Shieh, S.-C</creatorcontrib><creatorcontrib>Wu, Z.-C</creatorcontrib><creatorcontrib>Wang, W.-M</creatorcontrib><creatorcontrib>Wang, J.-D</creatorcontrib><creatorcontrib>Hung, C.-J</creatorcontrib><creatorcontrib>Lin, Y.-J</creatorcontrib><creatorcontrib>Chou, T.-C</creatorcontrib><creatorcontrib>Chan, R.-H</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Transplantation proceedings</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lee, P.-C</au><au>Chang, S.-S</au><au>Shieh, S.-C</au><au>Wu, Z.-C</au><au>Wang, W.-M</au><au>Wang, J.-D</au><au>Hung, C.-J</au><au>Lin, Y.-J</au><au>Chou, T.-C</au><au>Chan, R.-H</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cyclosporine or Tacrolimus: Which Is the Better Partner for Myfortic or CellCept?</atitle><jtitle>Transplantation proceedings</jtitle><addtitle>Transplant Proc</addtitle><date>2012</date><risdate>2012</risdate><volume>44</volume><issue>1</issue><spage>137</spage><epage>139</epage><pages>137-139</pages><issn>0041-1345</issn><eissn>1873-2623</eissn><coden>TRPPA8</coden><abstract>Abstract Background Mycophenolic acid (MPA) pharmacokinetics using the mycophenolate mofetil (CellCept) formulation are known to differ between patients receiving tacrolimus (FK) or cyclosporine (CyA), but only limited data exist concerning concomitant use of FK or CyA with enteric-coated mycophenolate sodium (EC-MPS; Myfortic). This retrospective study compared the drug interactions with the mycophenolic acid blood levels using different immunosuppressants and their relation to graft survival. Patients and methods We studied MPA levels in posttransplant sera from 298 renal transplant recipients. Results Patients receiving immunosuppression with CyA + Myfortic showed 94% at 5- and 10-year graft survivals, which were better than CyA + CellCept (75%, 63%). This combination suppressed posttransplant human leukocyte antigen (HLA) antibody development significantly ( P = .03) with higher MPA levels. Conclusion Patients immunosuppressed with CyA + Myfortic showed higher MPA levels and lower posttransplant HLA antibody development as well as the best graft survival. CyA + Myfortic or FK + Cellcept may be better combinations.</abstract><cop>Amsterdam</cop><pub>Elsevier Inc</pub><pmid>22310598</pmid><doi>10.1016/j.transproceed.2011.12.023</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0041-1345 |
| ispartof | Transplantation proceedings, 2012, Vol.44 (1), p.137-139 |
| issn | 0041-1345 1873-2623 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_920370313 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | Antibacterial agents Antibiotics. Antiinfectious agents. Antiparasitic agents Biological and medical sciences Cyclosporine - therapeutic use Drug Interactions Drug Monitoring Drug Therapy, Combination Fundamental and applied biological sciences. Psychology Fundamental immunology Graft Rejection - immunology Graft Rejection - prevention & control Graft Survival - drug effects Histocompatibility - drug effects HLA Antigens - immunology Humans Immunosuppressive Agents - therapeutic use Isoantibodies - blood Kidney Transplantation - immunology Medical sciences Mycophenolic Acid - analogs & derivatives Mycophenolic Acid - blood Mycophenolic Acid - pharmacokinetics Mycophenolic Acid - therapeutic use Pharmacology. Drug treatments Retrospective Studies Surgery Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases Tacrolimus - therapeutic use Taiwan Tissue, organ and graft immunology Treatment Outcome |
| title | Cyclosporine or Tacrolimus: Which Is the Better Partner for Myfortic or CellCept? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-17T05%3A39%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cyclosporine%20or%20Tacrolimus:%20Which%20Is%20the%20Better%20Partner%20for%20Myfortic%20or%20CellCept?&rft.jtitle=Transplantation%20proceedings&rft.au=Lee,%20P.-C&rft.date=2012&rft.volume=44&rft.issue=1&rft.spage=137&rft.epage=139&rft.pages=137-139&rft.issn=0041-1345&rft.eissn=1873-2623&rft.coden=TRPPA8&rft_id=info:doi/10.1016/j.transproceed.2011.12.023&rft_dat=%3Cproquest_cross%3E920370313%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=920370313&rft_id=info:pmid/22310598&rft_els_id=S004113451101685X&rfr_iscdi=true |